Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.
A Randomized, Blinded, Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) (Adjuvanted) in Adults Aged 18 Years and Older.
調査の概要
状態
介入・治療
- 生物学的:Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted)
- 生物学的:Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant)
- 生物学的:Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant)
- 生物学的:Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Adjuvanted)
- 生物学的:Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Low adjuvant)
- 生物学的:Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Blank adjuvant)
- 生物学的:Normal Saline
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Xue Zhao, Master
- 電話番号:18168168075
- メール:zhaoxue@abbbio.com.cn
研究場所
-
-
Sichuan
-
Zigong、Sichuan、中国
- 募集
- Zigong Center for Disease Control and Prevention
-
コンタクト:
- Xue Zhao, Master
- 電話番号:18168168075
- メール:zhaoxue@abbbio.com.cn
-
主任研究者:
- Ting Huang, Bachelor
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Males or females aged 18 years and older at the time of enrollment (aged 18 years and older for the phase I part; aged 60 years and older for the phase II part), who are able to provide legal proof of identity.
- Voluntarily agree to participate in the trial, able to fully understand and sign the informed consent form.
- Able to attend all scheduled follow-up visits and comply with the requirements of the clinical trial protocol to complete the study.
Female participants must meet the following criteria: In the phase I part, women of childbearing potential* must have a negative pregnancy test prior to enrollment and be willing to use effective contraceptive measures for 12 months after receiving the investigational vaccine; in the phase II part, only women of non-childbearing potential will be enrolled.
- Women of childbearing potential: Defined as females who have experienced menarche and have not yet entered menopause, unless permanently sterile, such as documented bilateral salpingectomy, bilateral oophorectomy, or hysterectomy; menopause is defined as amenorrhea for 12 consecutive months without other medical cause.
[Effective contraceptive measures include: oral contraceptives, injectable contraceptives, subdermal implants or hormonal patches, intrauterine device (IUD), sterilization surgery, abstinence (no sexual intercourse), male condoms, etc.; rhythm method, withdrawal, and emergency contraception are not considered effective contraceptive measures.]
- Axillary body temperature ≤ 37.0°C measured on site prior to vaccination on the day of vaccination.
Exclusion Criteria:
- Clinically significant laboratory abnormalities that, in the investigator's comprehensive judgment, preclude enrollment (applicable only to the phase I part).
- Pregnant or breastfeeding women.
- A clear diagnosis of RSV infection or a history of RSV infection-related respiratory disease within 6 months prior to vaccination.
- Use of immunoglobulins or/and any blood products or plasma derivatives within 3 months prior to vaccination, or planned use during the study.
- Treatment with immunomodulators (including immunosuppressants and immunostimulants) within 6 months prior to vaccination (e.g., long-term use of systemic glucocorticoids for ≥14 days at a dose of ≥2 mg/kg/day or ≥20 mg/day prednisone or equivalent) (excluding inhaled, intra-articular, and topical steroids).
- Administration or planned use of long-acting immunomodulatory drugs (e.g., infliximab) at any time during the study.
- A history of severe allergic reactions (e.g., anaphylactic shock, allergic laryngeal edema, Henoch-Schönlein purpura, thrombocytopenic purpura, Arthus reaction) following any previous vaccination or drug use, or a family history of severe allergies.
- Impaired immune function or a diagnosis of congenital or acquired immunodeficiency, or human immunodeficiency virus (HIV) infection.
- A personal or family history of convulsions, epilepsy, encephalopathy, psychiatric disorders, or neurological diseases (such as Guillain-Barré syndrome, Miller Fisher syndrome).
- A diagnosis of lymphoproliferative disease or malignant tumor within 5 years.
- Clinically significant electrocardiogram (ECG) abnormalities as determined by the investigator (applicable only to the phase I part).
- Previous vaccination with any licensed or investigational RSV vaccine prior to enrollment, or planned vaccination during the study.
- Receipt of any vaccine within 14 days prior to vaccination, or any live vaccine within 30 days prior to vaccination.
- An acute disease or an acute exacerbation of a chronic disease within 3 days prior to vaccination, or use of antipyretic, analgesic, or anti-allergy medications.
- Suspected or known alcohol abuse or alcohol dependence (referring to a drinking pattern that causes serious mental or physical health problems) or drug abuse.
- A history of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection.
- Severe or unstable chronic diseases, including but not limited to cardiovascular diseases [e.g., hypertension uncontrolled by medication (on-site blood pressure measurement prior to vaccination: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg), coronary heart disease, myocarditis, pericarditis, atrial fibrillation], metabolic diseases (e.g., poorly controlled diabetes), hematological disorders (e.g., severe anemia, hemophilia), hepatic or renal diseases, digestive system diseases, respiratory system diseases (e.g., chronic obstructive pulmonary disease, active pulmonary tuberculosis, other severe respiratory diseases).
Note: For participants aged 60 years and older, those with pre-existing stable disease may be enrolled. This is defined as participants who may have underlying conditions such as hypertension or diabetes, provided that symptoms and signs are stable and medically controllable as assessed by the investigator prior to vaccination, and who have not required changes to the treatment/medication regimen or hospitalization due to the underlying condition within 3 months.
- A history of confirmed immune-mediated/autoimmune diseases (e.g., cold agglutinin hemolytic anemia, lymphadenopathy, eosinophilia, systemic lupus erythematosus, gout, hyperuricemia, acute disseminated encephalomyelitis, immune thrombocytopenia, autoimmune aplastic anemia, autoimmune neutropenia, autoimmune lymphoproliferative syndrome, thrombocytopenic purpura).
- Asplenia or functional asplenia, as well as any condition resulting in asplenia or splenectomy.
- Currently participating in or planning to participate in another clinical study involving investigational or unregistered products (drugs, vaccines, medical devices, etc.) during this study.
- Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in this clinical trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:プラセボ群
|
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
実験的:Investigational Vaccine 1 (Low Dose) Group
|
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
実験的:Investigational Vaccine 2 (Low Dose) Group
|
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
実験的:Investigational Vaccine 1 Group
|
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
実験的:Investigational Vaccine 2 Group
|
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
実験的:Investigational Vaccine 3 Group
|
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
|
プラセボコンパレーター:Adjuvant Control Group
|
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of solicited (local and systemic) adverse events (AEs) within 14 days post-vaccination.
時間枠:Within 14 days post-vaccination.
|
Within 14 days post-vaccination.
|
|
|
Incidence of unsolicited AEs within 30 days post-vaccination.
時間枠:Within 30 days post-vaccination.
|
Within 30 days post-vaccination.
|
|
|
Incidence of clinically significant laboratory abnormalities(blood biochemistry, blood routine, coagulation function, urinalysis) on Day 3 post-vaccination, and incidence of clinically significant ECG abnormalities on Days 3, 14, and 30 post-vaccination.
時間枠:On Days 3, 14, and 30 post-vaccination
|
Applicable to Phase I only
|
On Days 3, 14, and 30 post-vaccination
|
|
Incidence of serious adverse events (SAEs) and adverse events of special interest (AESIs) within 12 months post-vaccination.
時間枠:Within 12 months post-vaccination.
|
Within 12 months post-vaccination.
|
|
|
At 1 month post-vaccination: geometric mean titer (GMT) of neutralizing antibodies against RSV-A and RSV-B.
時間枠:At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: seroresponse rate (SRR) of neutralizing antibodies against RSV-A and RSV-B.
時間枠:At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: geometric mean fold rise (GMFR) of neutralizing antibodies against RSV-A and RSV-B.
時間枠:At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: geometric mean concentration (GMC) of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
時間枠:At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
時間枠:At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
時間枠:At 1 month post-vaccination
|
Applicable to Phase Ⅱ only
|
At 1 month post-vaccination
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
At 1 month post-vaccination: GMT of neutralizing antibodies against RSV-A and RSV-B.
時間枠:At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: SRR of neutralizing antibodies against RSV-A and RSV-B.
時間枠:At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: GMFR of neutralizing antibodies against RSV-A and RSV-B.
時間枠:At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: GMC of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
時間枠:At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
時間枠:At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 1 month post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
時間枠:At 1 month post-vaccination
|
Applicable to Phase I only
|
At 1 month post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMT of neutralizing antibodies against RSV-A and RSV-B.
時間枠:At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: SRR of neutralizing antibodies against RSV-A and RSV-B.
時間枠:At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMFR of neutralizing antibodies against RSV-A and RSV-B.
時間枠:At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMC of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
時間枠:At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
時間枠:At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
時間枠:At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 6 months, 12 months, and 24 months post-vaccination
|
|
At 14 days, 1 month, and 6 months post-vaccination: counts of CD4+ and CD8+ T cells expressing at least two activation markers (IFN-γ, IL-2, TNF-α, CD40L)
時間枠:At 14 days, 1 month, and 6 months post-vaccination
|
Applicable to Phase Ⅱ only
|
At 14 days, 1 month, and 6 months post-vaccination
|
協力者と研究者
捜査官
- 主任研究者:Ting Huang, Bachelor、Sichuan Center for Disease Control and Prevention
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- aRSV-ZHSW-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。